{
    "relation": [
        [
            "",
            "Albiglutide Process 2",
            "Albiglutide Process 3"
        ],
        [
            "Description",
            "During the BE Phase, participants received a single dose of albiglutide 30 milligrams (mg) from the Process 2 drug product, injected subcutaneously into the abdomen using a fixed-dose, prefilled, single-use injector pen.",
            "During the BE Phase, participants received a single dose of albiglutide 30 mg from the Process 3 drug product, injected subcutaneously into the abdomen using a fixed-dose, prefilled, single-use injector pen."
        ]
    ],
    "pageTitle": "Pharmacokinetics/Pharmacodynamics of Albiglutide - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01357889?sect=Xg0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990114.79/warc/CC-MAIN-20150728002310-00050-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 866131139,
    "recordOffset": 866114174,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups This study was comprised of a Screening Period (up to 2 weeks), a Run-in Period (4 weeks), a Treatment Period (TP: 17 weeks), and a Follow-up (8 weeks) Period. The TP had a Single-dose Phase (Bioequivalence [BE] Phase: 28 days) and a 12-week Multiple-dose Phase. In the BE Phase, 186 participants were randomized; 167 received >=1 treatment dose. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details The enrollment number reflects the 283 participants starting the Multiple-dose Phase. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: albiglutide (GSK716155) Intervention: Diabetes Mellitus, Type 2 Condition:",
    "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 Single-dose Phase (BE Phase: 28 Days) \u00a0 \u00a0 Albiglutide Process 2 \u00a0 \u00a0 Albiglutide Process 3 \u00a0 STARTED \u00a0 \u00a0 86 \u00a0 \u00a0 81 \u00a0 COMPLETED \u00a0 \u00a0 82 \u00a0 \u00a0 79 \u00a0 NOT COMPLETED \u00a0 \u00a0 4 \u00a0 \u00a0 2 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Persistent Hyperglycemia \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Physician Decision \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}